408 related articles for article (PubMed ID: 22761271)
1. Off spells and dyskinesias: pharmacologic management of motor complications.
Khan TS
Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
[TBL] [Abstract][Full Text] [Related]
2. Other pharmacological treatments for motor complications and dyskinesias.
Waters C
Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
[TBL] [Abstract][Full Text] [Related]
3. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
6. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
7. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Gottwald MD
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
[TBL] [Abstract][Full Text] [Related]
8. Mid-stage parkinsonism with mild motor fluctuations.
Tolosa E; Valldeoriola F
Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
10. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease--levodopa complications.
King DB
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
[TBL] [Abstract][Full Text] [Related]
12. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
Maranis S; Tsouli S; Konitsiotis S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
[TBL] [Abstract][Full Text] [Related]
13. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
14. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
16. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
17. [Update on current care guidelines. Parkinson's disease].
Reijo M; Atula S; Heikkinen E; Jaakkola MR; Pekka J; Keränen T; Martikainen K; Pekkonen E; Sotaniemi K;
Duodecim; 2010; 126(19):2289-90. PubMed ID: 21086687
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Bhidayasiri R; Ling H
J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
[TBL] [Abstract][Full Text] [Related]
19. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
